Techniques: Co-crystal structure of human cytomegalovirus (CMV) glycoprotein B and a broadly neutralizing antibody (bNAb) against CMV to aid vaccine design

Drug

Read the full 13 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE